Integra LifeSciences Holdings (IART) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology.
Total Cash From Operating Activities Chart for Integra LifeSciences Holdings
Integra LifeSciences Holdings (IART) operating cash flow for FY2025 was USD 50.4M, a -61.1% change from FY2024. Integra LifeSciences Holdings's operating cash flow moved from USD -5.6M in 1995 to USD 50.4M in 2025 over 30 years. Operating cash flow compound annual growth rate: 5-year CAGR of -24.4%, 10-year CAGR of -6.1%, 20-year CAGR of -0.6%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $926.27M
- Implied Share Price
- $11.91
- Enterprise Value
- $3.02B
- Revenue (TTM)
- $1.66B
- EBITDA
- $311.51M
- Profit Margin
- 0.79%
- Trailing P/E
- 70.06
- Forward P/E
- 6.00
- Price/Book (MRQ)
- 1.19
- Price/Sales (TTM)
- 0.56
- EV/EBITDA
- 12.32
- EV/Revenue
- 1.83
- Dividend Yield
- —
- Book Value
- $13.41
- Free Cash Flow (FY2025)
- -$45.25M
- Free Cash Flow Yield
- -4.89%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.